Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMARCA2 | P51531 | 9/20 | 0.65 |
| ▸ | SMARCA4 | P51532 | 8/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | AR | P10275 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | TYK2 | P29597 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31718481 | 0.89 | SMARCA2 (0.61) | SMARCA2SMARCA4POLBMEN1KMT2A | |
| SCHEMBL7933383 | 0.88 | SMARCA2 (0.59) | SMARCA2SMARCA4POLBARMEN1 | |
| SCHEMBL27481922 | 0.85 | SMARCA2 (0.57) | SMARCA2SMARCA4MEN1KMT2ALMNA | |
| SCHEMBL9599834 | 0.85 | SMARCA2 (0.86) | SMARCA2SMARCA4MEN1KMT2ALMNA | |
| SCHEMBL17796335 | 0.84 | HPGD (0.58) | SMARCA2SMARCA4POLBLMNAMAPK1 | |
| SCHEMBL5141436 | 0.83 | KMT2A (0.58) | SMARCA2SMARCA4POLBMEN1KMT2A | |
| SCHEMBL1400789 | 0.83 | SMARCA2 (0.68) | SMARCA2SMARCA4ARJAK2TYK2 | |
| SCHEMBL9278345 | 0.81 | SMARCA2 (0.65) | SMARCA2SMARCA4ARJAK2TYK2 | |
| SCHEMBL4175713 | 0.81 | SMARCA2 (0.66) | SMARCA2SMARCA4MEN1KMT2AJAK2 | |
| SCHEMBL31434913 | 0.81 | SMARCA2 (0.66) | SMARCA2SMARCA4MEN1KMT2AJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043076-A1 | Substituted 2-arylmethylene-n-aryl-n'aryl-malonamides and analogs as activators of caspases and inducers of apoptosis | CYTOVIA, INC. | 2007-02-22 | — | — | US | disclosed |
| WO-2005037196-A2 | SUBSTITUTED 2-ARYLMETHYLENE-N-ARYL-N'-ARYL-MALONAMIDES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS | CYTOVIA, INC. (US) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043076-A1 | Substituted 2-arylmethylene-n-aryl-n'aryl-malonamides and analogs as activators of caspases and inducers of apoptosis | CASP14, CASP2, CASP3 | SMARCA2 1938/4885SMARCA4 2622/4885POLB 3544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.